Dual-target RNA reduces abnormal bone formation in mice
An experimental RNA approach reduced abnormal bone formation in a mouse model of a rare genetic disease. Targeting both the altered ACVR1 gene and an inflammatory pathway worked better than either target alone in a single peer-reviewed study. A combined molecule also showed experimental efficacy, but effectiveness and the safety of prolonged treatment in people remain unestablished.
Science··Morning
Mutant-gene and inflammation targets work together
An experimental RNA approach reduced abnormal bone formation in mice modelling fibrodysplasia ossificans progressiva, a rare genetic disease in which bone can form in muscle and other soft tissues. The single peer-reviewed study appeared on October 16. Researchers designed small interfering RNA to suppress an altered copy of ACVR1 while largely preserving the normal gene’s function. A second RNA targeted interleukin-1β, a signal associated with inflammation.[1]
Combining the targets improved experimental efficacy
The team examined both prevention and treatment after trauma in the mouse model. Suppressing the altered gene reduced abnormal bone formation, and adding the inflammatory target was more effective than either pathway alone. Fatty-acid attachment supported delivery into tissues. Researchers then combined the two targets in one molecular structure. With local and systemic administration, its muscle accumulation and experimental efficacy were comparable to giving the separate molecules together.[1]
Human effectiveness and long-term safety remain open
The findings come from animal and experimental cell systems, without demonstrating treatment effectiveness in patients. Unintended suppression of normal ACVR1 requires further assessment, and the authors call for monitoring normal-gene expression in future clinical studies. Short-term tolerability cannot establish safety over a lifetime, especially when inflammation is repeatedly suppressed in children. RNA interference reduces gene expression without permanently editing DNA. Dosing, distribution and long-term safety still need study before this approach can be evaluated as a human treatment.[1]
